胆管がんの世界市場レポート 2025年

胆管がん市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR13.1％で10億2,000万米ドルに成長します。予測期間中の成長は、精密医療の採用の増加、ヘルスケア支出の増加、遺伝子検査の普及拡大、小売薬局の人気拡大によるものです。主要動向としては、診断技術の発展、臨床検査の拡大、診断におけるAIの統合、ドラッグデリバリーシステムの革新、医薬品開発の継続的な進展などが挙げられます。

肝疾患の罹患率の増加が胆管がん市場の成長を牽引すると予想されます。肝疾患には、肝炎、肝硬変、脂肪性肝疾患、肝がんなど、肝臓の機能や構造を損なうさまざまな疾患が含まれます。肝疾患の有病率の増加は、肥満、糖尿病、飲酒、ウイルス性肝炎感染などの危険因子に起因しています。特に慢性炎症と肝硬変は、胆管障害と悪性細胞の形質転換を促進することにより、胆管がんの開発に寄与します。例えば、2024年12月、英国の政府機関であるOffice for Health Improvement and Disparitiesは、アルコール性肝疾患による早期死亡が2022年の5,776例に対し、2023年は3.6％増加し、5,984例に達したと報告しました。その結果、肝疾患の罹患率の上昇が胆管がん市場の成長に拍車をかけています。

胆管がん市場の主要企業は、患者の予後を改善するために標的治療などの革新的な治療に注力しています。標的療法は、がんの成長を促進する特定の遺伝子、タンパク質、分子に作用するように設計されています。これらのプロセスを阻害することで、標的療法は腫瘍の進行を遅らせ、副作用を最小限に抑え、治療効果を高めることができます。例えば、2023年8月、日本を拠点とする製薬会社である大鵬薬品工業株式会社は、がん治療の開発を開始しました。日本の製薬会社である大鵬薬品工業株式会社は、FGFR2遺伝子融合による切除不能な胆道がんの治療として、FGFR阻害剤であるLYTGOBI（フトバチニブ）を発表しました。LYTGOBIは、FGFRシグナルを選択的かつ不可逆的に阻害し、化学療法後に進行した胆管がん症例において腫瘍の成長を遅らせ、患者の予後を改善するのに役立ちます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場-マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の胆管がんPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の胆管がん市場：成長率分析
• 世界の胆管がん市場の実績：規模と成長、2019～2024年
• 世界の胆管がん市場の予測：規模と成長、2024～2029年、2034年
• 世界の胆管がん総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の胆管がん市場：がん別、実績と予測、2019～2024年、2024～2029年、2034年
• 肝内胆管がん
• 肝外胆管がん
• 世界の胆管がん市場：製品別、実績と予測、2019～2024年、2024～2029年、2034年
• カペシタビン
• 5-フルオロウラシル
• オキサリプラチン
• ゲムシタビン
• シスプラチン
• 世界の胆管がん市場：療法別、実績と予測、2019～2024年、2024～2029年、2034年
• 標的薬剤療法
• 化学療法
• 免疫療法
• 世界の胆管がん市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
• 経口
• 皮下
• 静脈内
• 世界の胆管がん市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• 小売薬局
• eコマース
• 世界の胆管がん市場、肝内胆管がんのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 末梢肝内胆管がん
• 腫瘤形成性肝内胆管がん
• 世界の胆管がん市場、肝外胆管がんのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ペリヒラー胆管がん
• 遠位胆管がん

第7章 地域別・国別分析

• 世界の胆管がん市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の胆管がん市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 胆管がん市場：競合情勢
• 胆管がん市場：企業プロファイル
  • F. Hoffmann-La Roche Ltd
  • Merck & Co. Inc.
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • AstraZeneca PLC

第31章 その他の大手企業と革新的企業

• Novartis AG
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Boston Scientific Corporation
• Servier Laboratories
• Incyte Corporation
• Exelixis Inc.
• Hutchison China MediTech Limited
• Zymeworks Inc.
• Agios Pharmaceuticals Inc.
• RenovoRx Inc.
• Specialised Therapeutics Pty Ltd
• Ascletis Pharma Inc.
• Tiziana Life Sciences Ltd.
• Taiho Pharmaceutical Co. Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

• 胆管がん市場、2029年：新たな機会を提供する国
• 胆管がん市場、2029年：新たな機会を提供するセグメント
• 胆管がん市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第36章 付録

Cholangiocarcinoma is a malignant tumor that develops in the bile ducts, which transport bile from the liver to the small intestine. It is characterized by the uncontrolled growth of abnormal cells, leading to bile duct obstruction and liver dysfunction. Common symptoms include jaundice, abdominal pain, weight loss, and fatigue. Early diagnosis and timely treatment are essential for improving prognosis and disease management.

The primary types of cholangiocarcinoma are intrahepatic and extrahepatic cholangiocarcinoma. Intrahepatic cholangiocarcinoma (ICC) is a rare and aggressive form of liver cancer that originates within the liver's bile ducts. Treatment options vary based on different product types, including capecitabine, 5-fluorouracil, oxaliplatin, gemcitabine, and cisplatin. Available therapies include targeted drug therapy, chemotherapy, and immunotherapy, which are administered through oral, subcutaneous, or intravenous routes. These treatments are distributed through hospital pharmacies, retail pharmacies, and e-commerce platforms.

The cholangiocarcinoma market research report is one of a series of new reports from The Business Research Company that provides cholangiocarcinoma market statistics, including the cholangiocarcinoma industry global market size, regional shares, competitors with the cholangiocarcinoma market share, detailed cholangiocarcinoma market segments, market trends, and opportunities, and any further data you may need to thrive in the cholangiocarcinoma industry. This cholangiocarcinoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cholangiocarcinoma market size has grown rapidly in recent years. It will grow from $0.55 billion in 2024 to $0.63 billion in 2025 at a compound annual growth rate (CAGR) of 13.4%. The growth during the historic period can be credited to the increasing incidence of liver and bile duct cancers, rising awareness of rare cancers, a growing focus on personalized treatment, the expansion of immunotherapy approaches, and the rising geriatric population.

The cholangiocarcinoma market size is expected to see rapid growth in the next few years. It will grow to $1.02 billion in 2029 at a compound annual growth rate (CAGR) of 13.1%. The growth during the forecast period can be credited to the increasing adoption of precision medicine, rising healthcare expenditure, the growing prevalence of genetic testing, and the expanding popularity of retail pharmacies. Key trends include advancements in diagnostic techniques, the expansion of clinical trials, the integration of AI in diagnostics, innovations in drug delivery systems, and continued progress in drug development.

The increasing incidence of liver disease is expected to drive the growth of the cholangiocarcinoma market. Liver disease encompasses various conditions that impair the liver's function or structure, including hepatitis, cirrhosis, fatty liver disease, and liver cancer. The rising prevalence of liver disease is attributed to risk factors such as obesity, diabetes, alcohol consumption, and viral hepatitis infections. Chronic inflammation and cirrhosis, in particular, contribute to the development of cholangiocarcinoma by promoting bile duct damage and malignant cell transformation. For instance, in December 2024, the Office for Health Improvement and Disparities, a UK-based government agency, reported that premature deaths from alcoholic liver disease increased by 3.6% in 2023, reaching 5,984 cases compared to 5,776 in 2022. As a result, the rising incidence of liver disease is fueling growth in the cholangiocarcinoma market.

Leading companies in the cholangiocarcinoma market are focusing on innovative treatments, such as targeted therapies, to improve patient outcomes. Targeted therapies are designed to act on specific genes, proteins, or molecules that drive cancer growth. By blocking these processes, targeted therapies can slow tumor progression, minimize side effects, and enhance treatment effectiveness. For instance, in August 2023, Taiho Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, introduced LYTGOBI (futibatinib), an FGFR inhibitor, for the treatment of unresectable biliary tract cancer with FGFR2 gene fusions. LYTGOBI selectively and irreversibly inhibits FGFR signaling, helping to slow tumor growth and improve patient outcomes in cholangiocarcinoma cases that have progressed after chemotherapy.

In July 2023, Lucence, a US-based precision health company, partnered with Innovent Biologics Inc. to enhance bile duct cancer diagnostics. As part of this collaboration, Innovent sponsored Lucence's LiquidMARK Bile Duct test for eligible patients in Hong Kong, aiming to improve diagnostic accuracy and expand treatment options. Innovent Biologics Inc. is a China-based biotechnology company specializing in innovative therapies, including treatments for cholangiocarcinoma. This partnership underscores the growing focus on precision diagnostics to enhance early detection and personalized treatment strategies in the cholangiocarcinoma market.

Major players in the cholangiocarcinoma market are F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boston Scientific Corporation, Servier Laboratories, Incyte Corporation, Exelixis Inc., Hutchison China MediTech Limited, Zymeworks Inc., Agios Pharmaceuticals Inc., RenovoRx Inc., Specialised Therapeutics Pty Ltd, Ascletis Pharma Inc., Tiziana Life Sciences Ltd., and Taiho Pharmaceutical Co. Ltd.

North America was the largest region in the cholangiocarcinoma market in 2024. The regions covered in cholangiocarcinoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cholangiocarcinoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cholangiocarcinoma market consists of revenues earned by entities by providing services such as diagnostic testing and imaging, surgical services, and supportive treatments to manage symptoms and improve patient outcomes. The market value includes the value of related goods sold by the service provider or included within the service offering. The cholangiocarcinoma market also includes sales of advanced imaging systems, molecular diagnostic tests, and drugs. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cholangiocarcinoma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cholangiocarcinoma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cholangiocarcinoma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cholangiocarcinoma market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Cancer: Intrahepatic Cholangiocarcinoma; Extrahepatic Cholangiocarcinoma
• 2) By Product: Capecitabine; 5-Fluorouracil; Oxaliplatin; Gemcitabine; Cisplatin
• 3) By Therapy: Targeted Drug Therapy; Chemotherapy; Immunotherapy
• 4) By Route Of Administration: Oral; Subcutaneous; Intravenous
• 5) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; E-Commerce
• Subsegments:
• 1) By Intrahepatic Cholangiocarcinoma: Peripheral Intrahepatic Cholangiocarcinoma; Mass-Forming Intrahepatic Cholangiocarcinoma
• 2) By Extrahepatic Cholangiocarcinoma: Perihilar Cholangiocarcinoma; Distal Cholangiocarcinoma
• Companies Mentioned: F. Hoffmann-La Roche Ltd; Merck & Co. Inc.; AbbVie Inc.; Bristol-Myers Squibb Company; AstraZeneca PLC
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Cholangiocarcinoma Market Characteristics

3. Cholangiocarcinoma Market Trends And Strategies

4. Cholangiocarcinoma Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Cholangiocarcinoma Growth Analysis And Strategic Analysis Framework

• 5.1. Global Cholangiocarcinoma PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Cholangiocarcinoma Market Growth Rate Analysis
• 5.4. Global Cholangiocarcinoma Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Cholangiocarcinoma Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Cholangiocarcinoma Total Addressable Market (TAM)

6. Cholangiocarcinoma Market Segmentation

• 6.1. Global Cholangiocarcinoma Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intrahepatic Cholangiocarcinoma
• Extrahepatic Cholangiocarcinoma
• 6.2. Global Cholangiocarcinoma Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Capecitabine
• 5-Fluorouracil
• Oxaliplatin
• Gemcitabine
• Cisplatin
• 6.3. Global Cholangiocarcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Targeted Drug Therapy
• Chemotherapy
• Immunotherapy
• 6.4. Global Cholangiocarcinoma Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Subcutaneous
• Intravenous
• 6.5. Global Cholangiocarcinoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• E-Commerce
• 6.6. Global Cholangiocarcinoma Market, Sub-Segmentation Of Intrahepatic Cholangiocarcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Peripheral Intrahepatic Cholangiocarcinoma
• Mass-Forming Intrahepatic Cholangiocarcinoma
• 6.7. Global Cholangiocarcinoma Market, Sub-Segmentation Of Extrahepatic Cholangiocarcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Perihilar Cholangiocarcinoma
• Distal Cholangiocarcinoma

7. Cholangiocarcinoma Market Regional And Country Analysis

• 7.1. Global Cholangiocarcinoma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Cholangiocarcinoma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Cholangiocarcinoma Market

• 8.1. Asia-Pacific Cholangiocarcinoma Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Cholangiocarcinoma Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Cholangiocarcinoma Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Cholangiocarcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Cholangiocarcinoma Market

• 9.1. China Cholangiocarcinoma Market Overview
• 9.2. China Cholangiocarcinoma Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Cholangiocarcinoma Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Cholangiocarcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Cholangiocarcinoma Market

• 10.1. India Cholangiocarcinoma Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Cholangiocarcinoma Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Cholangiocarcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Cholangiocarcinoma Market

• 11.1. Japan Cholangiocarcinoma Market Overview
• 11.2. Japan Cholangiocarcinoma Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Cholangiocarcinoma Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Cholangiocarcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Cholangiocarcinoma Market

• 12.1. Australia Cholangiocarcinoma Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Cholangiocarcinoma Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Cholangiocarcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Cholangiocarcinoma Market

• 13.1. Indonesia Cholangiocarcinoma Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Cholangiocarcinoma Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Cholangiocarcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Cholangiocarcinoma Market

• 14.1. South Korea Cholangiocarcinoma Market Overview
• 14.2. South Korea Cholangiocarcinoma Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Cholangiocarcinoma Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Cholangiocarcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Cholangiocarcinoma Market

• 15.1. Western Europe Cholangiocarcinoma Market Overview
• 15.2. Western Europe Cholangiocarcinoma Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Cholangiocarcinoma Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Cholangiocarcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Cholangiocarcinoma Market

• 16.1. UK Cholangiocarcinoma Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Cholangiocarcinoma Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Cholangiocarcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Cholangiocarcinoma Market

• 17.1. Germany Cholangiocarcinoma Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Cholangiocarcinoma Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Cholangiocarcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Cholangiocarcinoma Market

• 18.1. France Cholangiocarcinoma Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Cholangiocarcinoma Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Cholangiocarcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Cholangiocarcinoma Market

• 19.1. Italy Cholangiocarcinoma Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Cholangiocarcinoma Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Cholangiocarcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Cholangiocarcinoma Market

• 20.1. Spain Cholangiocarcinoma Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Cholangiocarcinoma Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Cholangiocarcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Cholangiocarcinoma Market

• 21.1. Eastern Europe Cholangiocarcinoma Market Overview
• 21.2. Eastern Europe Cholangiocarcinoma Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Cholangiocarcinoma Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Cholangiocarcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Cholangiocarcinoma Market

• 22.1. Russia Cholangiocarcinoma Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Cholangiocarcinoma Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Cholangiocarcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Cholangiocarcinoma Market

• 23.1. North America Cholangiocarcinoma Market Overview
• 23.2. North America Cholangiocarcinoma Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Cholangiocarcinoma Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Cholangiocarcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Cholangiocarcinoma Market

• 24.1. USA Cholangiocarcinoma Market Overview
• 24.2. USA Cholangiocarcinoma Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Cholangiocarcinoma Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Cholangiocarcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Cholangiocarcinoma Market

• 25.1. Canada Cholangiocarcinoma Market Overview
• 25.2. Canada Cholangiocarcinoma Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Cholangiocarcinoma Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Cholangiocarcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Cholangiocarcinoma Market

• 26.1. South America Cholangiocarcinoma Market Overview
• 26.2. South America Cholangiocarcinoma Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Cholangiocarcinoma Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Cholangiocarcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Cholangiocarcinoma Market

• 27.1. Brazil Cholangiocarcinoma Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Cholangiocarcinoma Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Cholangiocarcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Cholangiocarcinoma Market

• 28.1. Middle East Cholangiocarcinoma Market Overview
• 28.2. Middle East Cholangiocarcinoma Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Cholangiocarcinoma Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Cholangiocarcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Cholangiocarcinoma Market

• 29.1. Africa Cholangiocarcinoma Market Overview
• 29.2. Africa Cholangiocarcinoma Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Cholangiocarcinoma Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Cholangiocarcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Cholangiocarcinoma Market Competitive Landscape And Company Profiles

• 30.1. Cholangiocarcinoma Market Competitive Landscape
• 30.2. Cholangiocarcinoma Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

31. Cholangiocarcinoma Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Takeda Pharmaceutical Company Limited
• 31.3. Eli Lilly and Company
• 31.4. Boston Scientific Corporation
• 31.5. Servier Laboratories
• 31.6. Incyte Corporation
• 31.7. Exelixis Inc.
• 31.8. Hutchison China MediTech Limited
• 31.9. Zymeworks Inc.
• 31.10. Agios Pharmaceuticals Inc.
• 31.11. RenovoRx Inc.
• 31.12. Specialised Therapeutics Pty Ltd
• 31.13. Ascletis Pharma Inc.
• 31.14. Tiziana Life Sciences Ltd.
• 31.15. Taiho Pharmaceutical Co. Ltd.

32. Global Cholangiocarcinoma Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cholangiocarcinoma Market

34. Recent Developments In The Cholangiocarcinoma Market

35. Cholangiocarcinoma Market High Potential Countries, Segments and Strategies

• 35.1 Cholangiocarcinoma Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Cholangiocarcinoma Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Cholangiocarcinoma Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer